Bladder cancer patients whose surgery was delayed more than 3 months after diagnosis were more likely to die from their disease than were patients whose surgery was performed sooner, according to a recent study by researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor.
Bladder cancer patients whose surgery was delayed more than 3 months after diagnosis were more likely to die from their disease than were patients whose surgery was performed sooner, according to a recent study by researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor.
The study, published in the Journal of Urology (2006; 175:1262-7), followed 214 patients diagnosed with muscle-invasive bladder cancer and treated with radical cystectomy. Thirty-nine percent of patients without a 93-day delay to surgery died compared with 54% of patients whose surgery was delayed more than 93 days. The patients whose surgery was delayed lived only 1 year on average, and their 3-year survival rate was 38%, compared with the 3-year survival rate of 51% for patients whose surgery was not delayed.
The most common reason for delay was scheduling issues. Less-frequent reasons were patients seeking multiple opinions, misdiagnosis, or patients reluctant to be treated.
“Most of these causes for delaying surgery are potentially reversible, and physicians-despite busy schedules and the need for second opinions-need to be diligent about coordinating appointments and information in a timely way,” said lead author Cheryl Lee, MD.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.